AstraZeneca to Invest $2 Billion in Summit Therapeutics, Boost Cancer Drug Collaboration
The pharmaceutical giant's investment signals a deepening partnership aimed at advancing novel cancer treatments.
Business & Markets • 2 hours ago
AstraZeneca has announced a significant investment of $2 billion in Summit Therapeutics, a move that will also expand their collaboration on developing new cancer drugs. Following the announcement, Summit Therapeutics' shares saw a notable surge in after-hours trading.
The investment underscores a strengthening strategic alliance between the two companies. Their collaborative efforts are primarily focused on the advancement of innovative cancer treatments, aiming to leverage combined expertise and resources to bring promising therapies to patients.